drugset / Trial / NCT03800810

Implantation of Allogenic Mesenchymal Stem Cell From Umbilical Cord Blood for Osteoarthritis Management

NCT03800810

Phase 0 Unknown 9 enrolled Indonesia University
RandomizedParallel-groupTriple-blindTreatment

Summary

Prevalence of osteoarthritis increases every year, as a chronic and progressive disease. Osteoarthritis also gives many negative impacts in socio-economic life. Current management of osteoarthritis only aimed to relieve pain but not to resolve the degeneration of cartilage. Mesenchymal stem cell is one kind of adult stem cell that has potency in tissue engineering. Sources of mesenchymal stem cell are bone marrow, adipose tissue and umbilical cord. Researchers want to explore the potential of umbilical cord as the source of allogeneic MSC, because the gaining process of MSC is not invasive. Some countries have started some In vitro studies, Animal studies, and human research, but in Indonesia the study of mesenchymal stem cell implantation from umbilical cord in genu osteoarthritis management has not been reported. This study will be held into two years in Cipto Mangunkusumo Hospital and include 9 participants minimally. The researcher also compares the efficacy and safety of MSC implantation from umbilical cord applied to genu osteoarthritis with synovial artificial and recombinant human growth hormone therapy.

Timeline

Start
2015-05
Primary completion
2019-05
Completion
2019-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Recombinant Human Somatropin Protein / enzyme biologic 8 iu Other
Subject Umbilical Cord Mesenchymal Stem Cell Cell therapy 1e+07 cells Other
Background Hyaluronic Acid Other / unclassified 2 ml Other

Indications